Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Indaptus Therapeutics Inc (INDP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INDP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25
1 Year Target Price $25
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.79% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.73M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 1 | Beta 1.15 | 52 Weeks Range 6.65 - 58.24 | Updated Date 08/15/2025 |
52 Weeks Range 6.65 - 58.24 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -37.38 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.19 | Actual -9.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -136.55% | Return on Equity (TTM) -755.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9112754 | Price to Sales(TTM) - |
Enterprise Value 9112754 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.03 | Shares Outstanding 1118260 | Shares Floating 589481 |
Shares Outstanding 1118260 | Shares Floating 589481 | ||
Percent Insiders 19.42 | Percent Institutions 5.21 |
Upturn AI SWOT
Indaptus Therapeutics Inc
Company Overview
History and Background
Indaptus Therapeutics Inc. is a biotechnology company focused on developing novel therapies for cancer. Founded relatively recently, it is in a stage of clinical trials and early-stage development.
Core Business Areas
- Cancer Immunotherapy: Developing and commercializing a new approach to cancer therapy that boosts the bodyu2019s innate immune response to tumors
Leadership and Structure
The company has a management team focused on clinical development and scientific innovation, overseen by a board of directors.
Top Products and Market Share
Key Offerings
- IL-12 Immunotherapeutic: This is Indaptus Therapeutics Inc's lead product candidate, an investigational drug intended for solid tumors and lymphomas. It is currently in clinical trials.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by aging populations, advancements in diagnostics, and new therapies. Cancer immunotherapy is a major sector within this market.
Positioning
Indaptus is positioned as an innovator in cancer immunotherapy.
Total Addressable Market (TAM)
The total addressable market is in the billions. Indaptus Therapeutics Inc. is trying to secure a piece of the market.
Upturn SWOT Analysis
Strengths
- Innovative Technology Platform
- Experienced Management Team
- Targeting High-Need Cancer Types
Weaknesses
- Limited Financial Resources
- Reliance on Single Product Candidate
- Limited Market Presence
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion to New Cancer Indications
- Positive Clinical Trial Results
Threats
- Competition from Established Cancer Therapies
- Regulatory Hurdles
- Clinical Trial Failures
Competitors and Market Share
Key Competitors
- MRNA
- BMY
- PFE
Competitive Landscape
Indaptus competes with established oncology giants who have broad portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of product candidates through clinical stages.
Future Projections: Future growth is tied to successful clinical trial outcomes, regulatory approvals, and potential commercialization or partnering deals.
Recent Initiatives: Focus on clinical trials.
Summary
Indaptus Therapeutics Inc. is a early-stage biotechnology company focused on cancer immunotherapy. The company's future is heavily reliant on the successful development and commercialization of its product candidates. The current absence of revenue and considerable research and development expenses highlight the risks and opportunities involved in investing in this type of company. Success depends on clinical trials, regulatory approvals, and strategic partnerships to navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indaptus Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-08-04 | CEO & Director Mr. Jeffrey A. Meckler J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://indaptusrx.com |
Full time employees 7 | Website https://indaptusrx.com | ||
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.